Alembic Pharma share gains 3% on USFDA approval for antifungal drug
Alembic Pharma stock touched an intraday high of Rs 1106, rising 2.77% against the earlier closing of Rs 1,076.20 on BSE. The stock opened at Rs 1,078 and also touched an intraday low of Rs 1,075 ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's joint venture, Aleor Dermaceuticals Limited, has received US Food and Drug Administration (USFDA) Tentative Approval for Tavaborole Topical Solution, 5%. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Opening Of Trading Window
Pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives and our earlier communication dated 23rd July, 2020, the trading window for dealing in securities of the Company which was closed from 23rd July, 2020, is re-opened with immediate effect. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Shareholding for the Period Ended August 07, 2020
Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended August 07, 2020. For more details, kindly Click here ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Meeting Updates
Please note that the Fund Raising Committee of the board of directors of the Company ('Committee') has, at its meeting held today i.e. 7th August, 2020, approved the allotment of 80,47,210 Equity Shares of face value Rs. 2 each to eligible qualified institutional buyers at the issue price of Rs. 932 per Equity Share (including a premium of Rs. 930 per Equity Share) against the floor price of Rs. 980.75 per Equity Share, aggregating to approximately Rs. 750 crore (Rupees Seven Hundred and Fifty crore only), pursuant to the Issue. Pursuant to the allotment of Equity Shares in the Issue, the paid-up share capital of the Company has increased to Rs. 39,31,26,248, comprising of 19,65,63,124 Equity Shares of Rs. 2 each. Further, we have enclosed herewith the list of allottees who have been allotted more than five percent (5%) of the Equity Shares offered in the Issue, marked as Annexure A. The meeting of the Committee commenced at 10:45 a.m. and concluded at 11:15 a.m. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Outcome Of Fund Raising Committee Meeting Of The Board Of Directors
a. Approved the closure of the Issue today, i.e. 6th August, 2020; b. Determined and approved the issue price of Rs. 932.00 per Equity Share (including a premium of Rs. 930.00 per Equity Share), which takes into account a discount of 4.97% (i.e. Rs. 48.75 per Equity Share) to the floor price of Rs. 980.75 per Equity Share determined as per the formula prescribed under Regulation 176(1) of the SEBI ICDR Regulations, for the Equity Shares to be allotted to the eligible qualified institutional buyers in the Issue; c. Approved and adopted the placement document dated 6th August, 2020; and d. Approved and finalised the confirmation of allocation note to be sent to the eligible qualified institutional buyers, intimating them about the allocation of Equity Shares pursuant to the Issue. As intimated vide our letter dated 3rd August, 2020, the Issue had opened on 3rd August, 2020. The meeting of the Committee commenced at 7:30 p.m. and concluded at 8:00 p.m. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Meeting Updates
Outcome of Fund Raising Committee Meeting of the Board of Directors held today
Alembic Pharmaceuticals gets USFDA nod for erectile dysfunction drug
The approved product is therapeutically equivalent to the reference listed drug product Levitra tablets of Bayer Healthcare Pharmaceuticals Inc. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Vardenafil Hydrochloride Tablets, 2.5 mg (base), 5 mg (base), 10 mg (base), and 20 mg (base). Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Meeting Updates
In terms of Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'SEBI LODR Regulations'), we wish to inform you that a meeting of the Fund Raising Committee of the board of the directors of the Company is scheduled to be held on 6th August, 2020 inter alia to consider and approve the issue price, including a discount, if any, thereto as permitted under the SEBI ICDR Regulations, for the Equity Shares to be allotted to qualified institutional buyers, pursuant to the Issue. We request you to take the above on record and the same be treated as compliance under the applicable provisions of the SEBI LODR Regulations.